INmune Bio, Inc.
INMB
$1.63
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.05% | -41.18% | -61.83% | -90.97% | -81.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.05% | -41.18% | -61.83% | -90.97% | -81.25% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 19.05% | -41.18% | -61.83% | -90.97% | -81.25% |
| SG&A Expenses | -4.55% | -11.78% | -1.37% | -1.04% | 2.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.05% | 4.99% | 20.62% | 42.66% | 52.74% |
| Operating Income | 16.09% | -5.10% | -20.93% | -43.35% | -53.85% |
| Income Before Tax | -20.87% | -47.07% | -18.26% | -40.24% | -50.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.87% | -47.07% | -18.26% | -40.24% | -50.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.87% | -47.07% | -18.26% | -40.24% | -50.45% |
| EBIT | 16.09% | -5.10% | -20.93% | -43.35% | -53.85% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 1.90% | -21.27% | -1.84% | -27.65% | -42.89% |
| Normalized Basic EPS | 33.35% | 13.17% | -1.84% | -27.66% | -42.91% |
| EPS Diluted | 1.90% | -21.27% | -1.84% | -27.65% | -42.89% |
| Normalized Diluted EPS | 33.35% | 13.17% | -1.84% | -27.66% | -42.91% |
| Average Basic Shares Outstanding | 25.26% | 20.26% | 16.99% | 10.91% | 5.14% |
| Average Diluted Shares Outstanding | 25.26% | 20.26% | 16.99% | 10.91% | 5.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |